Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer ; day:26 ; month:10 ; year:2023 ; pages:1-4
Prostate cancer and prostatic diseases ; (26.10.2023), 1-4
- Creator
-
Jones, Robert Hugh
Fizazi, Karim
James, Nicholas D.
Tammela, Teuvo L.
Matsubara, Nobuaki
Priou, Frank
Beuzeboc, Philippe
Lesimple, Thierry
Bono, Petri
Kataja, Vesa
Garcia, Jorge A.
Protheroe, Andrew
Shore, Neal
Aspegren, John
Joensuu, Heikki
Kuss, Iris
Fiala-Buskies, Sabine
Vjaters, Egils
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41391-023-00740-9
- URN
-
urn:nbn:de:101:1-2024011511351438910250
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jones, Robert Hugh
- Fizazi, Karim
- James, Nicholas D.
- Tammela, Teuvo L.
- Matsubara, Nobuaki
- Priou, Frank
- Beuzeboc, Philippe
- Lesimple, Thierry
- Bono, Petri
- Kataja, Vesa
- Garcia, Jorge A.
- Protheroe, Andrew
- Shore, Neal
- Aspegren, John
- Joensuu, Heikki
- Kuss, Iris
- Fiala-Buskies, Sabine
- Vjaters, Egils
- SpringerLink (Online service)
Other Objects (12)
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate